Browsing by Subject "Alzheimer's disease"
Now showing items 1-11 of 11
-
AGE-RELATED WEIGHT LOSS IN THE 5XFAD MOUSE MODEL OF ALZHEIMER’S DISEASE: A BEHAVIOURAL AND HORMONAL ANALYSIS
(2015)The 5xFAD mice exhibit weight loss at 9 months of age. We investigated age-related changes in body weight, feeding behaviour, activity levels, feeding-related hormones, and proteins regulating adipogenesis and thermogenesis ... -
CHARACTERIZATION OF SOCIAL DEFICITS IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE
(2019-11-28)The 5xFAD mouse strain is a double-transgenic Alzheimer’s disease (AD) model containing mutant APP (K670N/M671L, I716V, and V717I) and PS1 (M146L and L286V) genes. Mice expressing these mutations have rapid accumulation ... -
Clinicopathological Correlates in Tauopathy and Aging
(2022-08-16)Cognitive decline can result from both neurodegenerative or normal aging processes. Definitive diagnosis of many neurodegenerative diseases, such as Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP), requires ... -
Conformational Characterization and Classification of Intrinsically Disordered Amyloid-beta( 1-42) Through Molecular Dynamics Simulations
(2022-10-07)Intrinsically disordered proteins (IDPs) are a group of proteins that lack the ability to fold into a well-defined 3D structure. These proteins comprise a significant fraction of eukaryotic proteomes. The free energy ... -
DEVELOPMENT OF BUTYRYLCHOLINESTERASE LIGANDS FOR THE IMAGING OF NEUROLOGICAL DISORDERS
(2013-08-12)Butyrylcholinesterase (BuChE) is a serine hydrolase enzyme that, along with acetylcholinesterase (AChE), catalyzes the hydrolysis of acetylcholine. These enzymes are associated with the pathology of neurologic disorders ... -
The discovery of a novel series of amyloid-β antiaggregants based on the structure of 3-hydroxyanthranilic acid: a detailed analysis of the mechanism of action underpinning antiaggregant activity
(2015-05-01)Alzheimer’s disease (AD) is the fourth leading cause of death in the industrialized nations, yet there are no disease-stabilizing therapies currently in use. The amyloid hypothesis suggests that oligomeric species of the ... -
DISRUPTION OF SLEEP AND CIRCADIAN RHYTHM ORGANIZATION AS RISK FACTORS FOR DIAGNOSIS OF ALZHEIMER’S DISEASE
(2016-08-26)Individuals commonly report disrupted nighttime sleep and daytime sleepiness in the early, preclinical, stages of Alzheimer’s disease (AD), as well as other dementias. Furthermore, there is accumulating evidence of a ... -
EFFECTS OF THE NOVEL IDO INHIBITOR DWG-1036 ON THE BEHAVIOUR AND NEUROCHEMISTRY OF THE TRIPLE TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE
(2017-08-30)Alzheimer’s disease (AD) is a neurodegenerative disorder causing memory loss as well as deficits in speech, motor performance and mood. Although the exact mechanisms causing the disease or how it progresses are not completely ... -
The In Silico Search for an Endogenous Anti-Alzheimer's Therapeutic
(2011-12-19)Alzheimer’s disease (AD) is a progressive, degenerative neurological disorder for which there is no cure. The causative agent is ?-amyloid (A?) which becomes neurotoxic upon conformational change from ?-helix to ?-sheet. ... -
MOLECULAR NEUROIMAGING IN ALZHEIMER'S DISEASE: TARGETING BUTYRYLCHOLINESTERASE (BCHE) FOR POSITRON EMISSION TOMOGRAPHY (PET) AND SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) IMAGING OF THE BRAIN
(2019-08-23)Currently, there are no effective means to definitively diagnose Alzheimer’s disease (AD) during life. Molecular imaging of β-amyloid (Aβ) or tau neurofibrillary tangle (NFT) pathology in the AD brain, though informative, ... -
The Relationship between Leisure Activity Participation, Language, and Literacy in Adults with Down Syndrome
(2013-08-21)The literature has stated that all adults with Down syndrome (DS) develop the physiological signs of Alzheimer's disease (AD), but that the behavioural changes may not occur until many years later. While there has been a ...
